ClinicalTrials.gg
CompletedNCT03378635Updated Jun 10, 2021Results posted

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

A Phase 3 interventional study of Dasiglucagon and GlucaGen in Hypoglycemia and Diabetes Mellitus, Type 1, sponsored by Zealand Pharma. Completed at 5 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-10.

Sponsored by Zealand Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies testing dasiglucagon in Hypoglycemia — none open to participants now, none under way, none of them phase 3. dasiglucagon · Hypoglycemia.

Enrollment
Largest of 16
170 · median 33
Started
2017
with 1 other
Phase 3
6 of 16
none open now
Registered
5th of 16
by date
Lead sponsor
11 of 16
Zealand Pharma

Among the 16 studies testing dasiglucagon in Hypoglycemia, this one has the largest enrollment, is one of 2 that started in 2017, is one of 6 in phase 3, and was the 5th registered.

Hypoglycemia

706 studies on the registry are indexed under Hypoglycemia; 94 are open to participants now.

Browse Hypoglycemia studies →

Open to participants now

None of the 16 studies testing dasiglucagon in Hypoglycemia is open now. The open studies under Hypoglycemia, anywhere →

About dasiglucagon

dasiglucagon: first FDA approval 2021 (ZEGALOGUE), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 59 Hypoglycemia studies recruiting now, 23 (39%) set no upper age limit and 31 (53%) stop at 75 or younger; 18 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing dasiglucagon in Hypoglycemia as a file.
02

Study summary

The objective of the trial is to demonstrate superiority of dasiglucagon compared to placebo following a single subcutaneous dose administered to subjects with type 1 diabetes mellitus (T1DM) with insulin-induced hypoglycemia. Additionally to compare the glycemic response observed after administration dasiglucagon with that of GlucaGen®.

Read the detailed description

This was a global, multicenter, randomized, parallel, and double-blind clinical trial confirming the efficacy and safety of dasiglucagon for insulin-induced hypoglycemia in patients with T1DM. The patients were randomized 2:1:1 to receive a single subcutaneous 0.6 mg dose of dasiglucagon, placebo, or a 1 mg dose of GlucaGen and followed for at least 28 days after receiving treatment.

03

Conditions studied

  • Hypoglycemia
  • Diabetes Mellitus, Type 1

Keywords

  • Dasiglucagon
  • Glucagon analog
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male subjects with type 1 diabetes mellitus (T1DM) for at least 1 year, diagnostic criteria as defined by the American Diabetes Association
  • Treated with insulin for T1DM for at least 1 year and with stable insulin treatment (defined as no more than a 10-unit daily variation in total daily insulin dose) 30 days prior to screening
  • \<10%

Exclusion criteria

Exclusion Criteria:

  • Previously treated with dasiglucagon (previously referred to as ZP4207)
  • Known or suspected allergy to trial product(s) or related products
  • Females who are pregnant according to a positive pregnancy test, are actively attempting to get pregnant, or are lactating.
  • History of hypoglycemic events associated with seizures in the last year prior to screening
  • History of severe hypoglycemia in the last month prior to screening
  • Active within the last 5 years
  • Current bleeding disorder, including anti-coagulant treatment
  • Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma (i.e. insulin secreting pancreas tumor)
  • Use of a daily systemic beta-blocker drug, indomethacin, warfarin or anticholinergic drugs in the previous 28 days before Day 1 of this trial
  • abnormal at screening as judged by the investigator
  • Donation of blood or plasma in the past month, or in excess of 500 mL within 12 weeks prior to screening
  • Surgery or trauma with significant blood loss within the last 2 months prior to screening
  • A positive result in the alcohol and/or urine drug screen at the screening visit. Significant history of alcoholism or drug abuse as judged by the investigator or consuming more than 24 g alcohol per day for men, or more than 12 g alcohol per day for women
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    Dasiglucagon

    Single fixed dose (s.c.injection) of dasiglucagon

    Drug: Dasiglucagon

  • Placebo comparator
    Placebo

    Single fixed dose (s.c.injection) of placebo

    Drug: Placebo

  • Active comparator
    GlucaGen®

    Single fixed dose (s.c.injection) of GlucaGen®

    Drug: GlucaGen

Interventions

  • Glucagon analog

    Also known as: ZP4207

  • Native glucagon

    Also known as: GlucaGen HypoKit

  • DrugPlacebo

    Placebo for dasiglucagon

    Also known as: Placebo for dasiglucagon

06

What researchers measure

Primary outcomes

  1. Time to Plasma Glucose Recovery

    Plasma glucose recovery is defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose. The outcome measure used a Kaplan-Meier estimate with 95% confidence interval. Treatment groups without censoring utilized a distribution free method to compute the confidence interval for median time.

    Time frame: 0-45 minutes after dosing

Secondary outcomes

  1. Plasma Glucose Recovery

    Plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after study drug injection without administration of rescue IV glucose. Plasma glucose recovery was defined as the first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose.

    Time frame: 0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injection

  2. Plasma Glucose Changes From Baseline

    Plasma glucose changes from baseline at 30 minutes, 20 minutes, 15 minutes and 10 minutes after study drug injection without administration of rescue intravenous glucose

    Time frame: 0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injection

  3. Time to Target

    Time to first plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) without administration of rescue intravenous glucose. The outcome measure used a Kaplan-Meier estimate with 95% confidence interval. Treatment groups without censoring utilized a distribution free method to compute the confidence interval for median time.

    Time frame: 0-45 minutes after dosing

  4. Pharmacodynamics - Area Under the Effect Curve

    Plasma glucose response as area under the effect curve (AUE) above baseline from time zero to 30 minutes. Samples were collected pre-dose, and at 4, 6, 8, 10, 12, 15, 17, 20, 25 and 30 minutes after dosing.

    Time frame: 0-30 minutes after dosing

  5. Pharmacokinetics - Area Under the Plasma Concentration Curve

    Area under the drug concentration curve from time zero to 90 minutes, AUC0-90min. To calculate the AUC the standard trapezoidal method was used, based on actual rather than nominal time points. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.

    Time frame: 0-90 minutes after dosing

  6. Pharmacokinetics - Area Under the Plasma Concentration Curve

    Area under the drug concentration curve from time zero to 120 minutes, AUC0-120min. To calculate the AUC the standard trapezoidal method was used, based on actual rather than nominal time points. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.

    Time frame: 0-120 minutes after dosing

  7. Pharmacokinetics - Maximum Plasma Concentration

    Maximum plasma drug concentration (Cmax). Maximum plasma drug concentration was determined as the maximum of all valid plasma dasiglucagon/glucagon concentrations. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.

    Time frame: 0-120 minutes after dosing

  8. Pharmacokinetics - Time to Maximum Plasma Concentration

    Time to maximum plasma drug concentration (tmax). Median Tmax was determined as the time point where the maximum of all valid plasma dasiglucagon/glucagon concentration measurements for each measurement series was observed. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.

    Time frame: 0-120 minutes after dosing

  9. Immunogenicity - Occurence of Anti-drug Antibodies

    Occurence of antibodies against dasiglucagon/GlucaGen

    Time frame: 28 days

  10. Rescue Infusion of IV Glucose During the Hypoglycemic Clamp Procedure

    Number of patients receiving administration of rescue infusion of IV glucose during the hypoglycemic clamp procedure. IV = intravenous

    Time frame: 0-45 minutes after dosing

  11. Time to First Rescue Infusion of IV Glucose

    Time to first rescue administration of rescue infusion of IV glucose. IV = intravenous

    Time frame: 0-45 minutes after dosing

07

Results

Posted May 10, 2021

Participant flow

Participant flow — Overall Study
MilestoneDasiglucagon 0.6 mgPlaceboGlucaGen® 1.0 mg
Started844343
Randomized and exposed to treatment824343
Completed824343
Not completed200
Withdrew: Adverse event100
Withdrew: Withdrawal by subject100

Outcome measures

PrimaryTime to Plasma Glucose Recovery

Plasma glucose recovery is defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose. The outcome measure used a Kaplan-Meier estimate with 95% confidence interval. Treatment groups without censoring utilized a distribution free method to compute the confidence interval for median time.

Time frame:
0-45 minutes after dosing
Reported as:
Median · minutes
Time to Plasma Glucose Recovery
minutesDasiglucagon 0.6 mgPlaceboGlucaGen® 1.0 mg
Time to Plasma Glucose Recovery10 (10 to 10)40 (30 to 40)12 (10 to 12)
Statistical analysis
  • Dasiglucagon 0.6 mg vs Placebo · Log Rank · p = <0.001
SecondaryPlasma Glucose Recovery

Plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, and within 10 minutes after study drug injection without administration of rescue IV glucose. Plasma glucose recovery was defined as the first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline without administration of rescue intravenous glucose.

Time frame:
0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injection
Reported as:
Count of participants · Participants
Plasma Glucose Recovery
ParticipantsDasiglucagon 0.6 mgPlaceboGlucaGen® 1.0 mg
Glucose recovery at 30 minutes822043
Glucose recovery at 20 minutes81642
Glucose recovery at 15 minutes81141
Glucose recovery at 10 minutes53021
Statistical analysis
  • Dasiglucagon 0.6 mg vs Placebo · Fisher Exact · p = <0.001 (p-value was \<0.001 at all time points (10, 15, 20 and 30 minutes))
SecondaryPlasma Glucose Changes From Baseline

Plasma glucose changes from baseline at 30 minutes, 20 minutes, 15 minutes and 10 minutes after study drug injection without administration of rescue intravenous glucose

Time frame:
0-30 minutes after dosing: assessed at 10, 15, 20 and 30 minutes after study drug injection
Reported as:
Mean · mg/dL
Plasma Glucose Changes From Baseline
mg/dLDasiglucagon 0.6 mgPlaceboGlucaGen® 1.0 mg
At 30 minutes90.9 ± 18.219.1 ± 13.088.5 ± 19.2
At 20 minutes59.7 ± 15.08.7 ± 10.858.4 ± 15.6
At 15 minutes43.5 ± 12.516.65 ± 6.8244.1 ± 14.0
At 10 minutes23.9 ± 9.84-0.14 ± 5.6522.0 ± 10.0
Statistical analysis
  • Dasiglucagon 0.6 mg vs Placebo · ANCOVA · p = <0.001 (The p-value was \<0.001 at all time points (10, 15, 20 and 30 minutes))
SecondaryTime to Target

Time to first plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) without administration of rescue intravenous glucose. The outcome measure used a Kaplan-Meier estimate with 95% confidence interval. Treatment groups without censoring utilized a distribution free method to compute the confidence interval for median time.

Time frame:
0-45 minutes after dosing
Reported as:
Median · minutes
Time to Target
minutesDasiglucagon 0.6 mgPlaceboGlucaGen® 1.0 mg
Time to Target8 (8 to 8)25 (20 to 30)8 (8 to 10)
Statistical analysis
  • Dasiglucagon 0.6 mg vs Placebo · Log Rank · p = <0.001
SecondaryPharmacodynamics - Area Under the Effect Curve

Plasma glucose response as area under the effect curve (AUE) above baseline from time zero to 30 minutes. Samples were collected pre-dose, and at 4, 6, 8, 10, 12, 15, 17, 20, 25 and 30 minutes after dosing.

Time frame:
0-30 minutes after dosing
Reported as:
Mean · mg*h/dL
Pharmacodynamics - Area Under the Effect Curve
mg*h/dLDasiglucagon 0.6 mgPlaceboGlucaGen® 1.0 mg
Pharmacodynamics - Area Under the Effect Curve21.0 ± 5.263.57 ± 2.8620.4 ± 5.49
Statistical analysis
  • Dasiglucagon 0.6 mg vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): 0.131 · 95% CI 0.1 to 0.171
SecondaryPharmacokinetics - Area Under the Plasma Concentration Curve

Area under the drug concentration curve from time zero to 90 minutes, AUC0-90min. To calculate the AUC the standard trapezoidal method was used, based on actual rather than nominal time points. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.

Time frame:
0-90 minutes after dosing
Reported as:
Geometric mean · pmol*h/L
Pharmacokinetics - Area Under the Plasma Concentration Curve
pmol*h/LDasiglucagon 0.6 mgGlucaGen® 1.0 mg
Pharmacokinetics - Area Under the Plasma Concentration Curve1430 ± 34.21300 ± 27.5
Statistical analysis
  • Dasiglucagon 0.6 mg vs GlucaGen® 1.0 mg · ANCOVA · p = 0.144 · Mean difference (net): 0.91 · 95% CI 0.801 to 1.033
SecondaryPharmacokinetics - Area Under the Plasma Concentration Curve

Area under the drug concentration curve from time zero to 120 minutes, AUC0-120min. To calculate the AUC the standard trapezoidal method was used, based on actual rather than nominal time points. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.

Time frame:
0-120 minutes after dosing
Reported as:
Geometric mean · pmol*h/L
Pharmacokinetics - Area Under the Plasma Concentration Curve
pmol*h/LDasiglucagon 0.6 mgGlucaGen® 1.0 mg
Pharmacokinetics - Area Under the Plasma Concentration Curve1770 ± 31.21490 ± 27.2
Statistical analysis
  • Dasiglucagon 0.6 mg vs GlucaGen® 1.0 mg · ANCOVA · p = 0.006 · Mean difference (net): 0.844 · 95% CI 0.749 to 0.951
SecondaryPharmacokinetics - Maximum Plasma Concentration

Maximum plasma drug concentration (Cmax). Maximum plasma drug concentration was determined as the maximum of all valid plasma dasiglucagon/glucagon concentrations. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.

Time frame:
0-120 minutes after dosing
Reported as:
Geometric mean · pmol/L
Pharmacokinetics - Maximum Plasma Concentration
pmol/LDasiglucagon 0.6 mgGlucaGen® 1.0 mg
Pharmacokinetics - Maximum Plasma Concentration1280 ± 37.71490 ± 34.5
SecondaryPharmacokinetics - Time to Maximum Plasma Concentration

Time to maximum plasma drug concentration (tmax). Median Tmax was determined as the time point where the maximum of all valid plasma dasiglucagon/glucagon concentration measurements for each measurement series was observed. Samples were collected pre-dose, and at 15, 30, 35, 40, 50, 60, 90 and 120 minutes after dosing.

Time frame:
0-120 minutes after dosing
Reported as:
Median · hours
Pharmacokinetics - Time to Maximum Plasma Concentration
hoursDasiglucagon 0.6 mgGlucaGen® 1.0 mg
Pharmacokinetics - Time to Maximum Plasma Concentration0.670 (0.250 to 1.00)0.250 (0.230 to 0.670)
SecondaryImmunogenicity - Occurence of Anti-drug Antibodies

Occurence of antibodies against dasiglucagon/GlucaGen

Time frame:
28 days
Reported as:
Count of participants · Participants
Immunogenicity - Occurence of Anti-drug Antibodies
ParticipantsDasiglucagon 0.6 mgGlucaGen® 1.0 mg
Anti-drug antibodies at follow-up day 2810
Anti-drug antibodies at second follow up00
SecondaryRescue Infusion of IV Glucose During the Hypoglycemic Clamp Procedure

Number of patients receiving administration of rescue infusion of IV glucose during the hypoglycemic clamp procedure. IV = intravenous

Time frame:
0-45 minutes after dosing
Reported as:
Count of participants · Participants
Rescue Infusion of IV Glucose During the Hypoglycemic Clamp Procedure
ParticipantsDasiglucagon 0.6 mgPlaceboGlucaGen® 1.0 mg
Rescue Infusion of IV Glucose During the Hypoglycemic Clamp Procedure000
SecondaryTime to First Rescue Infusion of IV Glucose

Time to first rescue administration of rescue infusion of IV glucose. IV = intravenous

Time frame:
0-45 minutes after dosing

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events (AEs) were collected from the first trial-related activity after the patient had signed the informed consent to the end of the follow-up period, i.e. over 28 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dasiglucagon 0.6 mg0/82 (0%)0/82 (0%)66/82 (80.5%)
Placebo0/43 (0%)0/43 (0%)14/43 (32.6%)
GlucaGen® 1.0 mg0/43 (0%)0/43 (0%)32/43 (74.4%)
Most frequent other events
Showing 10 of 40
Most frequent other events
EventDasiglucagon 0.6 mgPlaceboGlucaGen® 1.0 mg
NauseaGastrointestinal disorders45/821/4323/43
HypoglycemiaMetabolism and nutrition disorders23/825/439/43
VomitingGastrointestinal disorders19/821/439/43
HeadacheNervous system disorders10/822/435/43
NasopharyngitisInfections and infestations5/821/430/43
DiarrheaGastrointestinal disorders4/820/431/43
Injection site erythemaGeneral disorders1/822/432/43
DizzinessNervous system disorders0/820/432/43
PharyngitisInfections and infestations2/820/430/43
Back painMusculoskeletal and connective tissue disorders2/820/430/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dasiglucagon 0.6 mgPlaceboGlucaGen® 1.0 mgTotal
Mean39.2 ± 12.138.0 ± 13.140.2 ± 11.539.1 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Dasiglucagon 0.6 mgPlaceboGlucaGen® 1.0 mgTotal
Female32161563
Male502728105
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dasiglucagon 0.6 mgPlaceboGlucaGen® 1.0 mgTotal
Hispanic or Latino2237
Not Hispanic or Latino804140161
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dasiglucagon 0.6 mgPlaceboGlucaGen® 1.0 mgTotal
American Indian or Alaska Native0000
Asian3205
Native Hawaiian or Other Pacific Islander0011
Black or African American1124
White763939154
More than one race1012
Unknown or Not Reported1102
Region of Enrollment
Region of Enrollment(participants)Dasiglucagon 0.6 mgPlaceboGlucaGen® 1.0 mgTotal
Canada18101038
Austria330033
United States126624
Germany19272773
08

Study locations

5 sites
  • ProSciento
    Chula Vista, California 91911, United States
  • Clinical Research Center, Medizinische Universität Graz
    Graz, Austria
  • LMC Diabetes & Manna Research
    Toronto, Canada
  • Profil
    Mainz, Germany
  • Profil
    Neuss, Germany
09

References and documents

Publications

  • Pieber TR, Aronson R, Hovelmann U, Willard J, Plum-Morschel L, Knudsen KM, Bandak B, Tehranchi R. Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial. Diabetes Care. 2021 Jun 1;44(6):1361-1367. doi: 10.2337/dc20-2995. PubMed 35239971 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Apr 2018, 4 months.

Results were first posted in May 2021, 3 years after primary completion. A results delay was requested in May 2019.

Of 17 phase 3 interventional studies under Hypoglycemia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 29. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2017
First posted
Dec 20, 2017
StartActual
Dec 7, 2017
Primary completionActual
Apr 27, 2018
CompletionActual
May 25, 2018
Results delay requested
May 2, 2019
Results first posted
May 10, 2021
Last update
Jun 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03378635
Lead sponsor
Zealand Pharma
Responsible party
Sponsor
First posted
Dec 20, 2017
Start date
Dec 7, 2017
Primary completion
Apr 27, 2018
Completion
May 25, 2018
Results posted
May 10, 2021
Last update
Jun 10, 2021

Study contacts

Christina Sylvest, MSc Pharm
study director · Zealand Pharma

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dasiglucagon

Start the discussion